1 **A closer look at weight loss interventions in primary care: A systematic review and meta-**
2 **analysis**
3

4 Leigh Perreault[1], E. Seth Kramer[2], Peter C. Smith[2], Darren Schmidt[3] and Christos Argyropoulos[3]
5
6 [1]Department of Medicine; Division of Endocrinology, Metabolism and Diabetes; University of
7 Colorado Anschutz Medical Campus, Aurora, CO USA
8
9 [2] Department of Family Medicine; University of Colorado Anschutz Medical Campus, Aurora, CO
10 USA
11
12 [3]Department of Medicine; Division of Nephrology; University of New Mexico School of
13 Medicine, Albuquerque, NM USA
14
15 Corresponding author: Leigh Perreault, MD
16   University of Colorado Anschutz Medical Campus
17   P.O. Box 6511, mailstop F8106
18   Aurora, CO 80045 USA
19   Leigh.perreault@CUAnschutz.edu
20

21 Short title: weight loss in primary care
22

ABSTRACT

BACKGROUND: Weight loss observed in clinical trials has failed to translate into real world clinical settings. The aim of the current investigation was to quantify patient weight loss using various approaches tested in primary care and to unveil relevant contextual factors that could improve patient weight loss on a long-term basis.

METHODS: This systematic review and meta-analysis was limited to randomized clinical trials conducted in people with overweight or obesity in a primary care setting where the intervention was administered by a primary care provider for at least 6 months. The major outcome was patient weight loss. All investigators identified studies and independently abstracted data using COVIDENCE systematic review software.

RESULTS: The seven studies included 2,187 people with obesity who had weight-related comorbidities or risk factors. Strategies tested for patient weight loss included 1) anti-obesity medication, 2) the combination of anti-obesity medication, intensive lifestyle counseling and meal replacements, and 3) physician training to better counsel patients toward intensive lifestyle modification. Substantial heterogeneity in the outcomes was observed, as well as bias toward lack of published studies showing no effect. The random effect model estimated a treatment effect for the aggregate efficacy of primary care interventions -3.54 kg (95% CI: -5.61 kg to -1.47 kg). Interventions that included a medication component (alone or as part of a multipronged intervention) achieved a greater weight reduction by -2.94 kg (p<0.0001). In all interventions, efficacy declined with time (reduction in weight loss by 0.53 kg per six months, 95%CI: 0.04-1.0 kg, p-value=0.04).

CONCLUSIONS: Weight loss interventions administered by a primary care provider can lead to modest weight loss. Weight loss is approximately doubled if anti-obesity medication is part of the treatment strategy. Nevertheless, weight loss is attenuated over time and underscores the need for long-term treatment.

INTRODUCTION

Obesity continues to cast an enormous human and economic toll. As of 2018, the Centers for Disease Control and Prevention estimated that 73.6% of U.S. adults are considered overweight (e.g. body mass index (BMI) $\geq$ 25 kg/m^2) and 42.4% have obesity (e.g. BMI $\geq$ 30 kg/m^2) (1), collectively costing the health care system approximately $1.7T annually.(2) Obesity is being increasingly recognized not only as a risk factor for disease but a disease unto itself. (3) Despite this fact, only ~50% of people with a BMI of 50 kg/m^2 (considered morbid or extreme obesity) have a diagnosis of obesity (4) and <1% of people with any degree of overweight or obesity are offered anything other than lifestyle advice. (5) Given the paucity of certified "obesity expert" health care providers, this treatment gap can only be closed by systematically addressing the barriers to weight management in primary care.

Patient demand is high for weight management in primary care. A study by Sherson et al reported that most patients want to discuss weight loss with their physicians. (6) Specifically, patients value physician direction with their diet, physical activity and goal setting.(7) In addition, recent years have ushered in numerous and diverse options for weight management that extend signficantly beyond lifestyle advice. Medications for weight loss are being more extensively studied and demonstrating improved outcomes.(8-11) Bariatric surgery provides a possible option to address weight and reverse potentially life-threatening conditions such as heart disease and diabetes in both adolescents and adults.(12-15) Intensive behavioral therapy (IBT) for obesity is now a covered benefit under Medicare.(16) Together, primary care practice

transformation, reimbursement for obesity care and better therapies for weight management

suggest new and pragmatic approaches can emerge.

Weight loss observed in clinical trials has failed to translate into real world clinical settings. (5)

Most of these trials have tested one or more strategies for weight loss but not the context in

which the strategies will ultimately be deployed. The objective of the current systematic review

and meta-analysis is to determine weight loss in randomized clinical trials specifically conducted

in a primary care setting where a primary care provider adminstered the intervention for at

least six months. Our goal was to quantify patient weight loss using various approaches tested

in primary care and to unveil relevant contextual factors that could improve patient weight loss

on a long-term basis.

MATERIALS AND METHODS

PRISMA reporting guideline

This systematic review is reported according to the Preferred Reporting Items for Systematic

Reviews and Meta-analyses (PRISMA) statement extension for network meta-analysis (17) and

was conducted following an *a priori*–established protocol registered with PROSPERO

(CRD42021242344).

Selection criteria

Randomized clinical trials were included in this meta-analysis if they were conducted in a

primary care setting with the primary care provider (physician, physician assistant, or nurse

practitioner) administering the intervention for at least six months. Interventions administered

exclusively by a medical assistant, health coach, dietician, or behavioral health provider were

not included, even if they occurred in a primary care setting. Interventions referring patients

elsewhere (e.g. to a commercial weight loss program) were also not included, even if the

referral was placed by the primary care provider. The control condition may have been a

placebo pill and/or some minimal amount of lifestyle intervention offered to both groups

intended to resemble "usual care". This analysis is limited studies to included adults age ≥18

years old with a BMI ≥25 kg/m^2, with or without weight-associated comorbidities, that reported

absolute weight at baseline and at the end of follow-up in the intervention and control groups.

Search strategy

The search strategy was designed in consultation with an experienced medical librarian with

input from study investigators using various databases from inception to June 5, 2021.

COVIDENCE systematic review software (Veritas Health Innovation; Melbourne, Australia) was

used for screening, full-text review, and data extraction (Figure 1). COVIDENCE is the primary

tool used in Cochrane reviews accessing the Cochrane Central Register of Controlled Trials and

databases supporting the Central Register such as MEDLINE, EMBASE, Scopus, and Web of

Science. References were imported using the search terms: randomized clinical trial, obesity,

overweight, weight loss, primary care, general practice, family practice, internal medicine,

routine medical practice. Duplicate citations were removed. Studies advanced to full-text

review as long as weight change was the primary outcome. Further exclusions were applied to

ensure that only randomized controlled clinical trials conducted in a primary care setting with a

primary care provider administering the intervention for $\geq$6 months were retained (Figure 1).

Data abstraction and quality assessment

All authors participated independently in the screening and full-text review process described

above. Discrepancies were resolved by consensus. Quality assessment and risk of bias of

individual studies was assessed in the context of the primary outcome using the template

provided by COVIDENCE. The template stratified responses into high, low or unsure for

sequence generation (the method used to generate the allocation sequence should produce

comparable groups), allocation concealment (the method used to conceal the allocation

sequence should not have been foreseen in advance of, or during, enrollment), blinding of

participants and personnel (neither participants or personnel had knowledge of which

intervention a participant received), blinding of outcomes assessment (outcome assessors had

no knowledge of which intervention a participant received), incomplete outcome data (data

were complete with low attrition and exclusions from the analysis), selective reporting (low

probability of selective outcome reporting), and other sources of bias (no concerns about bias

not addressed in the other domains in the tool).

Outcomes

All outcomes were assessed at 6 months of intervention vs. control, and again at 12, 18, or 24

months as long as the intervention vs. control conditions were ongoing according to the

randomization. The primary outcome was weight change from baseline. Contextual factors of

interest focused largely on strategy employed in the intervention group, but patient

characteristics and control condition were also examined. When available, outcomes were

abstracted using study-reported modified intention-to-treat analysis (i.e. patients exposed at

least once to the intervention or control condition and had one post-randomization weight

assessment).

Statistical analysis

Publication bias was assessed using contour-enhanced funnel plots (18) to detect the area of

statistical significance in which studies were missing, and the statistical significance of funnel

plot asymmetry was analyzed with the random effects version of the Egger test. (19) To

generate this plot multiple treatment effects from individual studies (change from baseline

relative to control treatment at multiple time points and/or multiple interventions) were

synthesized via random effects meta-analysis to provide an overall treatment effect per study.

This approach was used to generate a summary forest plot from all studies considered. The

fixed effects model assumes that the treatment effect is the same across all trials, while the

random effects model assumes that the treatment effect varies between the trials. Statistical

heterogeneity within and across trials synthesized was quantified by the I^2 statistic and the

between study variance(τ^2), which was calculated by REstricted Maximum Likelihood (REML).

The p-value of the Q test was used to test for the statistical significance of the observed

heterogeneity. To explore the replicability of these findings we calculated the prediction

interval (20) (i.e. the 95% confidence interval for the treatment effects in a future trial). A

prediction interval that is narrow and overlapping with the confidence interval of the treatment

effect, suggests that future studies are unlikely to change the conclusion we can draw from the

currently available trials. Finally, a formal, multilevel meta-regression analysis was carried out

to explore the hypothesis that lifestyle modifications will have a different effect than

pharmacologic interventions. This hierarchical meta-regression was the primary means for

synthesizing evidence for our analysis and accounts for the correlation of outcomes due to the

common control group in interventions with multiple treatments assessed at multiple time-

points during each study. The analyses were conducted in Microsoft R open v4.0.2 packages

meta v4.13-0 (funnel plot/forest plot) and metafor v2.4-0 (Egger test, meta-regression). Data

and code for all analyses are available in the Supplement.

RESULTS

Quality and bias of the studies included

Based on the search terms, 5417 studies were imported for screening. Of those, 2196 were

found to be duplicates and were removed. Of the remaining, 3029 were omitted because of

misalignment with the primary outcome (e.g. studies of lifestyle interventions to improve

quality of life, not weight).   Reasons for excluding 177 of the final 184 studies is shown in

Figure 1. All authors participated in this process with proportionate agreement ranging from

88-98% and random probability agreement 81-98% (Cohen's kappa 0.39-0.55). Quality

assessment and risk of bias of individual studies was assessed in the context of the primary

outcome for the following parameters: sequence generation [5/7 high; 2/7 low], allocation

concealment [4/7 high; 3/7 low], blinding of participants and personnel [6/7 high; 1/7 low],

blinding of outcomes assessment [3/7 high; 4/7 low], incomplete outcome data [3/7 high; 3/7

low; 1/7 unsure], selective reporting, and other sources of bias [1/7 low; 6/7 unsure]).

Characteristics of the studies included

Only 7 studies met our full inclusion criteria (Table 1). (21-27) Most studies were conducted in people with obesity who also had risk factors for poor outcomes (i.e. high-risk race/ethnicity, pre-existing type 2 diabetes, prediabetes, hypertension, dyslipidemia or the metabolic syndrome). Five of the 7 studies were conducted in the U.S. – with 6 of 7 being multi-centered - in people 40-60 years old with BMI's mostly in the 30's. Two of the studies randomized physicians to receive training in weight management the use of which became the intervention for patients. Three studies randomized patients to anti-obesity medication vs. placebo, whereas two used anti-obesity medication in combination with intensive lifestyle counseling and meal replacements. Two studies reported on more than one active interventions: high vs. low dose of medication (24) and basic vs. enhanced lifestyle coaching. (27) No study randomized patients to lifestyle modification alone in a setting where the providers had not received additional training on the topic. Control conditions frequently used their respective national or local guidelines to advise patients on healthy eating, physical activity and behavior modification. Time spent on giving this advice was minimal (5-7 minutes) and was intended to resemble "usual care". Three of the studies (21, 23, 25) reported on the studied intervention at only one time-point, while the remaining studies reported on weight loss at different time points. Two of the studies (23, 26) reported outcome information on completers (Completer Analysis) and we could not ascertain the intention-to-treat status of the outcome in one study. (22) The remaining four studies reported outcomes using modified intention-to-treat.

Meta-analysis for weight loss outcomes

The seven studies included 2,187 individuals and reported 2,400 changes from baseline in the

intervention arm and 2,453 in the control arm. Forest plot of the seven studies is shown in

Figure 2. There was evidence of substantial heterogeneity (I^2 was 86%, τ^2 was 7.19 and p<

0.01). The fixed effect model estimated a treatment effect for the aggregate efficacy of primary

care interventions -2.82 kg (95% CI: -3.27 kg to -2.38 kg), that was substantially different from

the random effect estimate of -3.54 kg (95% CI: -5.61 kg to -1.47 kg). Considerable uncertainty

remains about the efficacy of interventions; the 95% prediction interval for the treatment effect

in future replications of such trials was rather wide: from nearly 11 kg of weight loss to nearly 4

kg of weight gain.

Funnel plot analyses (Figure 3) suggested the presence of publication bias: the plot itself was

asymmetric, and there appeared to be missing studies in the area of non-significant studies

(white area of the plot). In confirmation of these visual impressions, Egger's test was also

statistically significant (p=0.0005). Summary treatment effects for the studies reporting

multiple interventions at multiple time points is shown in Figure 4. For two of the trials

reported, there was evidence of treatment heterogeneity within each study. (26, 27)

Analyses of heterogeneity

In univariate multilevel modeling, using random effects at the study and follow-up (nested

within study levels), there was evidence for attenuation of the treatment effect with time, i.e. a

reduction in weight loss of about 0.5 kg per six months (p=0.04). Interventions that included a

medication component (either alone or as components of multipronged intervention) achieved

a greater weight reduction by -2.94 kg (p<0.0001). In multivariate multilevel meta-regressions

that included both covariates (type of intervention and duration of the intervention), the

estimated weight loss associated with a drug component was identical to that estimated by the

univariate model. In these models, there was also evidence for reduction of efficacy with time

(reduction in weight loss by 0.53 kg per six months, 95%CI: 0.04-1.0 kg, p-value=0.04). When

we analyzed intervention type by treatment time interactions, there was evidence for

differential attenuation of treatment effect for interventions that included a drug component.

While the loss of efficacy of interventions without a drug component was estimated to be 0.26

kg/6 months (95% CI -0.14 to 0.66 kg, p=0.20), the efficacy of interventions with drug

components attenuated at a rate of 0.44 kg/6months, 95%CI (0.34-0.53 kg/6 months, p-value

<0.001).

DISCUSSION

Obesity – with its many comorbid conditions – has now surpassed smoking as the leading cause

of preventable death in the United States.(28) Despite the fact that obesity is both treatable

and preventable, treating the comorbidities, rather than obesity *per se* has been the mainstay

of therapy. Reasons for lack of weight management prioritization are extensive and complex

but have included lack of clinician education on effective obesity management and processes

that systematically address weight loss and weight loss maintenance long-term. [6-8] There are

reasons to believe, however, that the paradigm may be shifting. Clinical trials testing

infrastructure for weight-prioritized visits in primary care (e.g. NCT04678752) coupled with

highly effective pharmacotherapy (29, 30) may make patient weight loss of 15-22% achievable.

Major findings from the current analysis show that patients lose ~3 kg (approximately 3% body

weight) when they are provided more than usual care by their primary care provider and that

the amount of weight loss approximates 6 kg (roughly 6% body weight) when anti-obesity

medication is part of the intervention. Nevertheless, weight regain is common underscoring

the need for long-term treatment and intensification.

Most people receive their health care in primary care – not by specialists, dieticians, or health

coaches – the vast majority of whom fail to maintain a normal body weight. (1) Although some

published data supports the use of commercial weight loss programs (31), their long-term use is

uncommon. Patients want help with their weight from their primary care provider and 77% of

those who receive help (vs. 33% that did not) (32) report positive behavior change and weight

loss. (33) The current analysis examined what *has been (hence could be) done* in primary care

for weight management. Interventions ranged from provider use of newly reinforced

knowledge in the area of behavior modification to multi-faceted approaches that included

intensive behavioral therapy, anti-obesity medications and meal replacements. Wide breadth

in the interventions tested led to substantial and residual heterogeneity in their treatment

effect. The random effects model estimated a mean patient weight loss of -3.54 kg.

Interventions that included a medication component (either alone or as components of

multipronged intervention) achieved a greater weight reduction by -2.94 kg. The latter finding

was unchanged when adjusting for all components of the intervention or its duration

supporting the independent benefit of anti-obesity medications. Together, multi-faceted

approaches appear to yield greater weight loss compared to lifestyle advice alone when

administered by a primary care provider, however, larger trials are needed to confirm the

magnitude of the benefit.

Weight nadir in clinical trials is consistently achieved between 6-12 months with weight regain

following, despite ongoing intensive lifestyle modification (34, 35) or pharmacotherapy. (36, 37)

Results from the current analysis are highly aligned with those previously reported. We

observed an average weight regain of 0.5 kg/6 months in the setting of ongoing active

intervention. Interestingly, despite greater weight loss being achieved in trials testing anti-

obesity medication, the weight regain was also greater (0.44 kg/6 months vs. 0.26 kg/6

months). The notion that rapid (vs. gradual) weight loss leads to greater weight regain has

been debunked (38, 39). Hence, the greater weight regain with anti-obesity medication use

may relate to the greater absolute weight loss achieved. Highly conserved evolutionary

adaptations for survival are sensitive to weight loss, including lowering energy expenditure (40)

and driving energy intake. (41) Hence, discontinuation of anti-obesity medication after weight

loss could explain the rapid weight regain. Advances in the field have made it clear that

successful treatment must be long-term.

This systematic review and meta-analysis ultimately revealed few studies quantifying patient

weight loss resulting from an intervention administered by a primary care provider. Those that

have exhibited considerable heterogeneity and carry uncertainty around whether the results

can be replicated. The included studies are collectively of moderate quality, but there appears

to be a bias toward missing non-significant studies, hence this analysis may over-estimate the

true effect of the interventions. An important strength, however, was that this analysis was not

limited to trials examining behavior modification for weight loss nor did it include auxiliary

personnel providing care. (42) It was intended to review the full breadth of what has been

(hence could be) done in routine medical practice using conventional workflow and established

scope of training for primary care providers.

It is worth noting that the control conditions were intended to simulate "usual care" – citing

medical guidelines or giving brief advice – widely acknowledging the lack of standard-of-care for

weight management. High intra-individual variability in response to weight loss interventions

(43) rightfully supports a patient-centered approach. Nevertheless, lack of consensus on

recommendations for a specific approach (44) perpetuates clinical inertia. Trials included in

this analysis that used established guidelines or "usual care" as the standard-of-care rendered

<1 kg of weight loss. (21-23, 26) Trials included in this analysis that utilized hypocaloric diets

and targets for physical activity as the standard-of-care rendered 2-5 kg of weight loss (24, 25,

27) making it clear that prescribed behavior modification is essential. Granularity as to the

details of the optimal behavior modification, however, remain elusive.

CONCLUSIONS

It is time to reframe the conversation such that weight management is the primary goal for

treating weight-related comorbidities. (45) To that end, this is the first systematic review and

meta-analysis to see what *has or could be done* by primary care providers for weight

management. Despite the highly pragmatic nature of this question, few clinical trials have

pursued the answer. Results demonstrate successful patient weight loss, particularly when

multiple strategies are used together. Results also show that weight regain is common,

especially after using anti-obesity medication – likely because of discontinuation. It is clear that

establishment of a standard-of-care is desperately needed as a first step toward treatment.

Layering of additional strategies and long-term treatment must follow to promote patient

weight loss and weight loss maintenance.

320
321   **ACKNOWLEDGEMENTS:** We acknowledge the assistance of Emileigh Willems, PhD and Krithika
322   Suresh, PhD in the data extraction. This work was funded by 1R18DK127003.
323

REFERENCES

1.   Centers for Disease Control and Prevention. Prevalence and trends of overweight and obesity in the United States 2016 [accessed June 30, 2022]. Available from: www.cdc.gov/obesity/data/adult.html.

2.   Milken Institute. Economic impact of excess weight now exceeds $17T 2018 [accessed June 30, 2022]. Available from: https://www.milkeninstitute.org/articles/economic-impact-excess-weight-now-exceeds-17-trillion-new-milken-institute-report-reveals.

3.   World Health Organization. Obesity and overweight 2018 [accessed June 30, 2022]. Available from: https://www.who.int/topics/obesity/en/.

4.   Crawford AG, Cote C, Couto J, Daskiran M, Gunnarsson C, Haas K, et al. Prevalence of obesity, type II diabetes mellitus, hyperlipidemia, and hypertension in the United States: findings from the GE Centricity Electronic Medical Record database. Popul Health Manag. 2010;13(3):151-61.

5.   Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocr Pract. 2016;22 Suppl 3:1-203.

6.   Sherson EA, Yakes Jimenez E, Katalanos N. A review of the use of the 5 A's model for weight loss counselling: differences between physician practice and patient demand. Fam Pract. 2014;31(4):389-98.

7.   Yoong SL, Carey M, Sanson-Fisher R, Grady A. A systematic review of behavioural weight-loss interventions involving primary-care physicians in overweight and obese primary-care patients (1999-2011). Public Health Nutr. 2013;16(11):2083-99.

8.   Bohula EA, Scirica BM, Inzucchi SE, McGuire DK, Keech AC, Smith SR, et al. Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial. Lancet. 2018;392(10161):2269-79.

9.   Bohula EA, Wiviott SD, McGuire DK, Inzucchi SE, Kuder J, Im K, et al. Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients. N Engl J Med. 2018;379(12):1107-17.

10.   Garber AJ. Anti-Obesity Pharmacotherapy and the Potential for Preventing Progression from Prediabetes to Type 2 Diabetes. Endocr Pract. 2015;21(6):634-44.

11.   Svanstrom H, Ueda P, Melbye M, Eliasson B, Svensson AM, Franzen S, et al. Use of liraglutide and risk of major cardiovascular events: a register-based cohort study in Denmark and Sweden. Lancet Diabetes Endocrinol. 2019;7(2):106-14.

12.   Carlsson LM, Sjoholm K, Karlsson C, Jacobson P, Andersson-Assarsson JC, Svensson PA, et al. Long-term incidence of microvascular disease after bariatric surgery or usual care in patients with obesity, stratified by baseline glycaemic status: a post-hoc analysis of participants from the Swedish Obese Subjects study. Lancet Diabetes Endocrinol. 2017;5(4):271-9.

13.   Fisher DP, Johnson E, Haneuse S, Arterburn D, Coleman KJ, O'Connor PJ, et al. Association Between Bariatric Surgery and Macrovascular Disease Outcomes in Patients With Type 2 Diabetes and Severe Obesity. JAMA. 2018;320(15):1570-82.

14.   Inge TH, Courcoulas AP, Jenkins TM, Michalsky MP, Helmrath MA, Brandt ML, et al. Weight Loss and Health Status 3 Years after Bariatric Surgery in Adolescents. N Engl J Med. 2016;374(2):113-23.

15.   Sjostrom L, Narbro K, Sjostrom CD, Karason K, Larsson B, Wedel H, et al. Effects of
bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357(8):741-52.
16.   Department of Health and Human Services. Intensive behavioral therapy (IBT) for
obesity [accessed June 30, 2022]
https://www.cms.gov/Medicare/Prevention/PrevntionGenInfo/medicare-preventive-
services/MPS-QuickReferenceChart-1.html#OBESITY_IBT.
17.   Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for
systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med.
2009;151(4):264-9, W64.
18.   Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Contour-enhanced meta-analysis
funnel plots help distinguish publication bias from other causes of asymmetry. J Clin Epidemiol.
2008;61(10):991-6.
19.   Sterne JAC, & Egger, M. . Regression methods to detect publication and other bias in
meta-analysis. In: H. R. Rothstein AJS, & M. Borenstein editor. Publication bias in meta-analysis:
Prevention, assessment, and adjustments Chichester, England: Wiley; 2005. p. 99–110.
20.   Higgins JP, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-
analysis. J R Stat Soc Ser A Stat Soc. 2009;172(1):137-59.
21.   Boesten JE, Kaper J, Stoffers HE, Kroon AA, van Schayck OC. Rimonabant improves
obesity but not the overall cardiovascular risk and quality of life; results from CARDIO-REDUSE
(CArdiometabolic Risk reDuctIOn by Rimonabant: the Effectiveness in Daily practice and its
USE). Fam Pract. 2012;29(5):521-7.
22.   Cohen MD, D'Amico FJ, Merenstein JH. Weight reduction in obese hypertensive
patients. Fam Med. 1991;23(1):25-8.
23.   Davis Martin P, Rhode PC, Dutton GR, Redmann SM, Ryan DH, Brantley PJ. A primary
care weight management intervention for low-income African-American women. Obesity (Silver
Spring). 2006;14(8):1412-20.
24.   Hauptman J, Lucas C, Boldrin MN, Collins H, Segal KR. Orlistat in the long-term
treatment of obesity in primary care settings. Arch Fam Med. 2000;9(2):160-7.
25.   Lindgarde F. The effect of orlistat on body weight and coronary heart disease risk profile
in obese patients: the Swedish Multimorbidity Study. J Intern Med. 2000;248(3):245-54.
26.   Ryan DH, Johnson WD, Myers VH, Prather TL, McGlone MM, Rood J, et al. Nonsurgical
weight loss for extreme obesity in primary care settings: results of the Louisiana Obese Subjects
Study. Arch Intern Med. 2010;170(2):146-54.
27.   Wadden TA, Volger S, Sarwer DB, Vetter ML, Tsai AG, Berkowitz RI, et al. A two-year
randomized trial of obesity treatment in primary care practice. N Engl J Med.
2011;365(21):1969-79.
28.   Taksler GB ea, editor Life-years lost to preventable causes-of-death in the U.S., 2014. .
The Society of General Internal Medicine 2017 Annual Meeting; 2017 April 19-22, 2017;
Washington, D.C.
29.   Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide
Once Weekly for the Treatment of Obesity. N Engl J Med. 2022.
30.   Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-
Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-
1002.

31.   Gudzune KA, Doshi RS, Mehta AK, Chaudhry ZW, Jacobs DK, Vakil RM, et al. Efficacy of
commercial weight-loss programs: an updated systematic review. Ann Intern Med.
2015;162(7):501-12.
32.   Sciamanna CN, Tate DF, Lang W, Wing RR. Who reports receiving advice to lose weight?
Results from a multistate survey. Arch Intern Med. 2000;160(15):2334-9.
33.   Rodondi N, Humair JP, Ghali WA, Ruffieux C, Stoianov R, Seematter-Bagnoud L, et al.
Counselling overweight and obese patients in primary care: a prospective cohort study. Eur J
Cardiovasc Prev Rehabil. 2006;13(2):222-8.
34.   Diabetes Prevention Program Research Group. Long-term effects of lifestyle
intervention or metformin on diabetes development and microvascular complications over 15-
year follow-up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol.
2015;3(11):866-75.
35.   Look Ahead Writing Group, Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, et al.
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med.
2013;369(2):145-54.
36.   le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DC, Van Gaal L, et al. 3 years of
liraglutide versus placebo for type 2 diabetes risk reduction and weight management in
individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017.
37.   Smith SR, Weissman NJ, Anderson CM, Sanchez M, Chuang E, Stubbe S, et al.
Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med.
2010;363(3):245-56.
38.   Purcell K, Sumithran P, Prendergast LA, Bouniu CJ, Delbridge E, Proietto J. The effect of
rate of weight loss on long-term weight management: a randomised controlled trial. Lancet
Diabetes Endocrinol. 2014;2(12):954-62.
39.   Vink RG, Roumans NJ, Arkenbosch LA, Mariman EC, van Baak MA. The effect of rate of
weight loss on long-term weight regain in adults with overweight and obesity. Obesity (Silver
Spring). 2016;24(2):321-7.
40.   Johannsen DL, Knuth ND, Huizenga R, Rood JC, Ravussin E, Hall KD. Metabolic slowing
with massive weight loss despite preservation of fat-free mass. J Clin Endocrinol Metab.
2012;97(7):2489-96.
41.   Sumithran P, Prendergast LA, Delbridge E, Purcell K, Shulkes A, Kriketos A, et al. Long-
term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365(17):1597-
604.
42.   Madigan CD, Graham HE, Sturgiss E, Kettle VE, Gokal K, Biddle G, et al. Effectiveness of
weight management interventions for adults delivered in primary care: systematic review and
meta-analysis of randomised controlled trials. BMJ. 2022;377:e069719.
43.   MacLean PS, Rothman AJ, Nicastro HL, Czajkowski SM, Agurs-Collins T, Rice EL, et al. The
Accumulating Data to Optimally Predict Obesity Treatment (ADOPT) Core Measures Project:
Rationale and Approach. Obesity (Silver Spring). 2018;26 Suppl 2:S6-S15.
44.   Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, et al.
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF
ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF
PATIENTS WITH OBESITYEXECUTIVE SUMMARYComplete Guidelines available at
https://www.aace.com/publications/guidelines. Endocr Pract. 2016;22(7):842-84.

45.   Lingvay I, Sumithran P, Cohen RV, le Roux CW. Obesity management as a primary
treatment goal for type 2 diabetes: time to reframe the conversation. Lancet.
2022;399(10322):394-405.
459
460

461   **Table 1. Studies included in this meta-analysis**

Citation	Unique inclusion criteria	Site(s)	Age	BMI	control	Intervention	Duration	Weight change
Boesten 2012	T2D or IFG	29 sites in the Netherlands	59.2	32.2	NHG Dutch guidelines (no strict diet; patient sets goals and is monitored)	Rimonabant 20 mg qd	12 months	+0.18 kg control vs. -4 kg in intervention
Cohen 1991	hypertension	1 site in the U.S.	59.5	34.1	"usual care"	Physicians trained to counsel patients on low calorie food choices	6 & 12 months	+0.56 kg control vs. -1.8 kg in intervention at 6 mo; +1.33 kg control vs. -0.88 kg in intervention at 12 mo
Davis Martin 2006	Low income African American women	2 sites in the U.S.	42	39	Physicians received 2h training on NHLBI guidelines	Physicians received 7h additional training on behavior change for weight loss and multi-disciplinary team made tailored recommendations	6 months	+0.25 kg control vs. -1.44 kg in intervention
Hauptman 2000		17 sites in the U.S.	42.4	36	Hypocaloric diet and limit alcohol	Control + orlistat 60 mg or 120 mg QAC	6 &12 months	-4.70 kg control vs. -6.92 kg in low dose and -8.0 kg in high dose intervention at 6 mo; -

							4.14 kg control vs. -7.08 kg in low dose and -7.94 kg in high dose intervention at 12 mo
Lindgarde 2000	T2D, hypertension or dyslipidemia	33 sites in Sweden	53.4	33.2	Mildly hypocaloric diet, 30 min/day walking, placebo pill	Control + Orlistat 120 mg QAC	12 months	-4.3 kg control vs. -5.6 kg in intervention
Ryan 2010	BMI$\geq$40 kg/m^2	7 sites in the U.S.	47.1	46.1	Mayo Clinic guidelines for healthy weight	Low calorie liquid diet, then meal replacements, anti-obesity medication and group behavioral therapy	12 & 24 months	-1.1 kg control vs. -17.2 kg intervention at 12 mo; -0.5 kg control vs. -12.7 kg intervention at 24 mo.
Wadden 2011	Metabolic syndrome	6 sites in the U.S.	51.5	38.5	Low calorie diet, 180 min/wk activity, 5-7 min advice from PCP every 3 mo	Control + 10-15 min advice from lifestyle coach every 3 mo, meal replacements and/or anti-obesity medications	6, 12, 18 & 24 months	-2 kg control vs. -6.6 kg intervention at 6 mo; -2.3 kg control vs. -7.1 kg intervention at 12 mo; -1.9 kg control vs. -5.8 kg intervention at 18 mo; -1.7 kg control vs. -4.6 kg intervention at 24 mo.

462 **Figure 1. PRISMA diagram for data handling**
463

464
465

466   **Figure 2:** Forest plot of control corrected change in body weight from baseline

467
468

469   **Figure 3:** Enhanced funnel plot for assessment of study heterogeneity

470
471

472 **Figure 4**. Synthesis of treatment effect from studies reporting multiple interventions at multiple
473 time points
474

Study	Intervention	Follow-up	Experimental Total	Mean	SD	Control Total	Mean	SD	Control Corrected Weight Loss (kg)	MD	95%-CI
Study = Cohen et al 1991											
	MDTR	6 months	15	-1.80	3.40	15	0.56	2.50		-2.36	[-4.50; -0.22]
	MDTR	12 months	15	-0.88	4.00	15	1.30	3.00		-2.18	[-4.71; 0.35]
Random effects model			30			30				-2.29	[-3.92; -0.65]
Heterogeneity: $I^2 = 0\%$, $\tau^2 = 0$, $p = 0.92$											
Study = Hauptman et al 2000											
	Orlistat 60mg	6 months	213	-6.92	9.34	212	-4.70	8.74		-2.22	[-3.94; -0.50]
	Orlistat 120mg	6 months	210	-8.00	8.41	212	-4.70	8.74		-3.30	[-4.94; -1.66]
	Orlistat 60mg	12 months	213	-7.08	7.88	212	-4.14	8.15		-2.94	[-4.46; -1.42]
	Orlistat 120mg	12 months	210	-7.94	8.26	212	-4.14	8.15		-3.80	[-5.37; -2.23]
Random effects model			846			848				-3.10	[-3.90; -2.29]
Heterogeneity: $I^2 = 0\%$, $\tau^2 = 0$, $p = 0.60$											
Study = Wadden et al 2011											
	BLC	6 months	131	-3.50	0.50	130	-2.00	0.50		-1.50	[-1.62; -1.38]
	EBLC	6 months	129	-6.60	0.50	130	-2.00	0.50		-4.60	[-4.72; -4.48]
	BLC	12 months	131	-3.40	0.60	130	-2.30	0.60		-1.10	[-1.25; -0.95]
	EBLC	12 months	129	-7.10	0.60	130	-2.30	0.60		-4.80	[-4.95; -4.65]
	BLC	18 months	131	-3.00	0.70	130	-1.90	0.70		-1.10	[-1.27; -0.93]
	EBLC	18 months	129	-5.80	0.70	130	-1.90	0.70		-3.90	[-4.07; -3.73]
	BLC	24 months	131	-2.90	0.70	130	-1.70	0.70		-1.20	[-1.37; -1.03]
	EBLC	24 months	129	-4.60	0.70	130	-1.70	0.70		-2.90	[-3.07; -2.73]
Random effects model			1040			1040				-2.64	[-3.76; -1.52]
Heterogeneity: $I^2 = 100\%$, $\tau^2 = 2.6059$, $p = 0$											
Study = Ryan et al 2010											
	MR+GBT+Drug	12 months	119	-13.10	1.20	89	-0.90	0.60		-12.20	[-12.45; -11.95]
	MR+GBT+Drug	24 months	10	-9.70	1.30	86	-0.40	0.70		-9.30	[-10.12; -8.48]
Random effects model			129			175				-10.78	[-13.62; -7.94]
Heterogeneity: $I^2 = 98\%$, $\tau^2 = 4.1096$, $p < 0.01$											
Heterogeneity: $I^2 = 100\%$, $\tau^2 = 9.3305$, $p = 0$											

475
476
477 BLC: Brief Lifestyle Coaching; EBLC: Enhanced Basic Lifestyle Coaching ; GBT: Group Behavioral
478 Therapy; MDTR: Physician Training; MR: Meal Replacement
479

480 **Supplement. Data and code for the meta-analysis**

Author	Year	Intervention	Arm	Outcome	N	FU	NAtOutcome	TE	TE.se	ITT
Boesten et al	2012	Control	Cntrl	Weight Loss	109	12	98	-0.18	3.3	ITT
Boesten et al	2012	Drug	Rimonabant 20mg	Weight Loss	113	12	92	-4	5.9	ITT
Martin et al	2006	Control	Cntrl	Weight Loss	73	6	65	0.2	2.9	CA
Martin et al	2006	Non-drug	MDTR	Weight Loss	71	6	52	-2	3.2	CA
Cohen et al	1991	Control	Cntrl	Weight Loss	15	12	15	1.3	3	NR
Cohen et al	1991	Non-drug	MDTR	Weight Loss	15	12	15	-0.88	4	NR
Cohen et al	1991	Control	Cntrl	Weight Loss	15	6	15	0.56	2.5	NR
Cohen et al	1991	Non-drug	MDTR	Weight Loss	15	6	15	-1.8	3.4	NR
Hauptman et al	2000	Control	Cntrl	Weight Loss	212	6	91	-4.7	8.74	ITT
Hauptman et al	2000	Drug	Orlistat 60mg	Weight Loss	213	6	120	-6.92	9.34	ITT
Hauptman et al	2000	Drug	Orlistat 120mg	Weight Loss	210	6	117	-8	8.41	ITT
Hauptman et al	2000	Control	Cntrl	Weight Loss	212	12	91	-4.14	8.15	ITT
Hauptman et al	2000	Drug	Orlistat 60mg	Weight Loss	213	12	120	-7.08	7.88	ITT
Hauptman et al	2000	Drug	Orlistat 120mg	Weight Loss	210	12	117	-7.94	8.26	ITT
Lindgarde et al	2000	Control	Cntrl	Weight Loss	186	12	186	-4.3	5.9	ITT
Lindgarde et al	2000	Drug	Orlistat 120mg	Weight Loss	190	12	190	-5.6	5.2	ITT
Ryan et al	2010	Control	Cntrl	Weight Loss	190	12	89	-0.9	0.6	CA
Ryan et al	2010	Combination	MR+GBT+Drug	Weight Loss	200	12	119	-13.1	1.2	CA
Ryan et al	2010	Control	Cntrl	Weight Loss	190	24	86	-0.4	0.7	CA
Ryan et al	2010	Combination	MR+GBT+Drug	Weight Loss	200	24	10	-9.7	1.3	CA
Wadden et al	2011	Control	Cntrl	Weight Loss	130	6	130	-2	0.5	ITT
Wadden et al	2011	Non-drug	BLC	Weight Loss	131	6	131	-3.5	0.5	ITT
Wadden et al	2011	Combination	EBLC	Weight Loss	129	6	129	-6.6	0.5	ITT
Wadden et al	2011	Control	Cntrl	Weight Loss	130	12	130	-2.3	0.6	ITT
Wadden et al	2011	Non-drug	BLC	Weight Loss	131	12	131	-3.4	0.6	ITT
Wadden et al	2011	Combination	EBLC	Weight Loss	129	12	129	-7.1	0.6	ITT
Wadden et al	2011	Control	Cntrl	Weight Loss	130	18	130	-1.9	0.7	ITT
Wadden et al	2011	Non-drug	BLC	Weight Loss	131	18	131	-3	0.7	ITT
Wadden et al	2011	Combination	EBLC	Weight Loss	129	18	129	-5.8	0.7	ITT
Wadden et al	2011	Control	Cntrl	Weight Loss	130	24	130	-1.7	0.7	ITT
Wadden et al	2011	Non-drug	BLC	Weight Loss	131	24	131	-2.9	0.7	ITT
Wadden et al	2011	Combination	EBLC	Weight Loss	129	24	129	-4.6	0.7	ITT

482
483

```
484  library(meta)
485  library(metafor)
486  library(xlsx)
487  rm(list=ls())
488  data<-read.xlsx("data.xlsx",sheetIndex = 1)
489  data$N[data$ITT!="ITT"]<-data$NAtOutcome[data$ITT!="ITT"]
490  noncontrol<-subset(data,Arm!="Cntrl")
491  control<-subset(data,Arm=="Cntrl")
492
493  ## intervention = X, control = Y
494  composite<-merge(noncontrol,control,by=c("Author","Year","FU"))
495
496  composite<-transform(composite,Study=paste(Author,Year,Arm.x),AUYR=paste(Author,Year))
497
498
499  composite<-composite[order(composite$FU,composite$Year),]
500  composite<-transform(composite,FU = paste(FU,"months"),Time=FU)
501
502
503
504  ## synthesize studies with multiple reported TE
505  fAUb<-metacont(n.e=N.x,mean.e=TE.x,sd.e=TE.se.x,
```

```
506        n.c=N.y,mean.c=TE.y,sd.c=TE.se.y,
507          studlab=AUYR,data=composite,prediction=F,byvar=AUYR,
508          method.tau="REML",bylab="Study",comb.fixed=FALSE,
509          subset=!is.element(Author,c("Lindgarde et al","Martin et al","Boesten et al")))
510
511    ## get rid of labels for the plot
512    fAUb$studlab<-rep("",length(fAUb$studlab))
513    png("forestbyAuthor.png",width=8,height=6,units="in",res=600,pointsize=10)
514    forest(fAUb,leftcols = c("studlab" ,"Arm.x","FU","n.e",
515                  "mean.e", "sd.e", "n.c", "mean.c", "sd.c"),
516       leftlabs = c("Intervention","Follow-up"),digits=2,digits.se = 2,
517       smlab="Control Corrected\nWeight Loss (kg)",fontsize=7,overall=FALSE)
518    dev.off()
519    ## funnel plot ;
520    ## aggregate studies and then do the funnel plot
521    fAU<-metacont(n.e=N.x,mean.e=TE.x,sd.e=TE.se.x,
522          n.c=N.y,mean.c=TE.y,sd.c=TE.se.y,
523          studlab=AUYR,data=composite,prediction=F,byvar=AUYR,
524          method.tau="REML",bylab="Study",comb.fixed=FALSE)
525    deriveddf<-data.frame(TE=fAU$TE.random.w,seTE=fAU$seTE.random.w,Study=fAU$bylevs)
526    ## sort by year
527    deriveddf<-transform(deriveddf,Year=substr(Study,nchar(Study)-4,nchar(Study)))
528    deriveddf<-deriveddf[order(deriveddf$Year),]
529    ffunel<-metagen(TE=TE,seTE=seTE,data=deriveddf,studlab = Study,method.tau="REML")
530
531
532    png("funnel.png",width=6,height=6,res=600,pointsize=10,units="in")
533    fun<-funnel(ffunel, random = TRUE,
534          level = 0.95, contour = c(0.9, 0.95, 0.99),
535          col.contour = c("grey90", "grey80", "grey70") ,
536          lwd = 1, cex = 1, pch = 16, studlab = TRUE, cex.studlab = 0.6,
537          xlim=c(-11,4),pos.studlab=c(3,3,4,3,4,1,2),xlab="Mean Difference in Weight (kg)")
538    legend(-10, 0.05,title="Study p-value",
539        legend=c("0.1 > p > 0.05", "0.05 > p > 0.01", "p< 0.01"),
540        fill = c("grey90", "grey80", "grey70"))
541    dev.off()
542    ## egger test
543    regtest(x=deriveddf$TE,sei=deriveddf$seTE, model="rma")
544    ## meta-analysis
545    png("meta-analysis.png",width=6.5,height=4,units="in",res=600)
546    forest(ffunel,prediction=T,smlab="Control Corrected\nWeight Loss (kg)",
547        digits=2,digits.se = 2,fontsize=7)
548    dev.off()
549
```

```
550    ##metaregression with the package metafor
551
552    ## prepare the data first
553    prepESC<-escalc(measure="MD",m1i=TE.x,sd1i=TE.se.x,n1i=N.x,
554        m2i=TE.y,sd2i=TE.se.y,n2i=N.y,data=composite,slab=AUYR)
555
556    ## random effect at the study level
557    TimeEffect<-rma.mv(yi,vi,data=prepESC, random = ~ 1 | AUYR/FU,mods=~I(Time/6))
558    DrugEffect<-rma.mv(yi,vi,data=prepESC, random = ~ 1 |
559    AUYR/FU,mods=~Intervention.x!="Non-drug")
560
561    TimeDrugEffect<-rma.mv(yi,vi,data=prepESC, random = ~ 1 |
562    AUYR/FU,mods=~I(Intervention.x!="Non-drug")+I(Time/6))
563    TimeDrugEffectInteract<-rma.mv(yi,vi,data=prepESC, random = ~ 1 |
564    AUYR/FU,mods=~I(Intervention.x!="Non-drug")*I(Time/6))
```